Measles Exposure in Pediatric ED: Isolation & PEP | MDster You are offline Back online! [ ](/) Specialities [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) [ Features ](https://mdster.com/features) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) Menu Specialities [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) [ Features ](https://mdster.com/features) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) [ Login ](https://mdster.com/auth/login) 1. [ Home ](https://mdster.com) 2. [ Blog ](https://mdster.com/blog) 3. [ Case Discussion ](https://mdster.com/blog?category=case-discussion) 4. Measles Exposure in the Pediatric ED: Isolation, PEP, Pitfalls [ Case Discussion ](https://mdster.com/blog?category=case-discussion) Measles Exposure in the Pediatric ED: Isolation, PEP, Pitfalls ================================================================ A case-based Pediatrics discussion of diagnosis, airborne precautions, public health response, and post-exposure prophylaxis for high-risk contacts as of March 2026. [ MDster Editorial Team ](https://mdster.com/about) · Mar 16, 2026 · 8 min read · 82 [ Reviewed by Dr. Ali Ragab, MBBCH, MSc, MCAI ](https://mdster.com/medical-reviewers/dr-ali-ragab) [Editorial Policy](https://mdster.com/editorial-policy) | [Corrections Policy](https://mdster.com/corrections) [ Board Review ](https://mdster.com/blog?tag=board-review) [ Emergency Medicine ](https://mdster.com/blog?tag=emergency-medicine) [ Pediatrics ](https://mdster.com/blog?tag=pediatrics) [ Infectious Diseases ](https://mdster.com/blog?tag=infectious-diseases) [ Measles ](https://mdster.com/blog?tag=measles) Share this article Share this post A 6-year-old with high fever, cough, coryza, conjunctivitis, Koplik spots, and a rash that starts at the hairline is not simply a febrile exanthem workup. In a crowded ED, he is an outbreak investigation in real time. As of March 5, 2026, CDC had reported 1,281 confirmed U.S. measles cases in 2026, most outbreak-associated, which is why the most dangerous delay is often operational rather than diagnostic: failure to isolate before the chart is complete. [\[1\]](#cite-1 "Reference [1]") Why this is measles until proven otherwise ------------------------------------------ The differential still matters. Adenovirus can give fever, conjunctivitis, and pharyngitis; rubella can give a cephalocaudal rash; scarlet fever and Kawasaki disease can create mucocutaneous confusion. But this combination is classic measles: toxic prodrome, the 3 Cs, Koplik spots, then a blanching maculopapular rash descending from face to trunk. The incubation period averages 11–12 days to prodrome, with rash around day 14, and the child is typically infectious from 4 days before until 4 days after rash onset. In severe immune compromise, contagiousness may last longer. [\[2\]](#cite-2 "Reference [2]") The pathophysiology explains both the presentation and the stakes. Measles enters via the respiratory tract, spreads to regional lymphoid tissue, then disseminates hematogenously; the exanthem reflects systemic infection rather than a purely cutaneous process. Just as important, measles produces clinically meaningful immune suppression, which helps explain why bacterial pneumonia, otitis media, and later neurologic complications are not side notes but part of the disease’s natural history. [\[3\]](#cite-3 "Reference [3]") The first hour: contain the outbreak before you finish the note --------------------------------------------------------------- Current CDC guidance is straightforward: mask the patient if tolerated, move him immediately to an airborne infection isolation room if available, or at minimum a private room with a closed door until transfer is possible. Staff entering the room should use a fit-tested N95 or higher respirator regardless of presumed immunity. Transport should be limited; if transport is necessary, the child stays masked and the route should minimize contact with others. Airborne precautions continue for 4 days after rash onset, but for immunocompromised patients they continue for the duration of illness. [\[4\]](#cite-4 "Reference [4]") The waiting room is part of the case. In healthcare settings, exposure includes sharing the same airspace with the patient or entering that airspace within 2 hours after the patient leaves. Consequently, the triage bay, hallways, registration desk, and any exam room used before isolation all need review. CDC notes that airborne infectivity can persist up to 2 hours; where air changes per hour are known, clearance can be estimated from ventilation tables rather than guessed. [\[5\]](#cite-5 "Reference [5]") In parallel, notify infection prevention and local public health immediately, not after laboratory confirmation. Presumptive immunity for healthcare personnel means written documentation of 2 measles-containing vaccine doses, laboratory evidence of immunity, laboratory confirmation of disease, or birth before 1957; verbal history is not enough. Exposed healthcare workers without presumptive immunity are typically excluded from work from day 5 after first exposure through day 21 after last exposure. [\[6\]](#cite-6 "Reference [6]") > **Clinical Pearl:** In suspected measles, diagnosis and outbreak control happen in parallel. If you wait for PCR before triggering exposure management, you are already behind. Confirm the diagnosis while treating the child ---------------------------------------------- Testing should be obtained at first contact: an NP or throat swab for rRT-PCR plus serum for measles IgM. PCR is most useful early. IgM can be falsely negative if drawn within the first 72 hours after rash onset, so a negative early serology does not rescue a weak clinical decision; if suspicion remains high, repeat serology and keep public health involved. Treatment remains supportive: hydration, oxygen as needed, and aggressive evaluation for complications such as pneumonia or bacterial superinfection. There is no specific antiviral therapy for routine measles. [\[7\]](#cite-7 "Reference [7]") For hospitalized or severe pediatric measles, vitamin A belongs in the conversation. CDC, consistent with pediatric guidance, recommends 2 doses given on consecutive days: 50,000 IU for infants younger than 6 months, 100,000 IU for 6–11 months, and 200,000 IU for children 12 months and older. That said, vitamin A is supportive therapy, not post-exposure prophylaxis, and the pregnancy caveat matters because high preformed vitamin A intake is undesirable in pregnancy. [\[8\]](#cite-8 "Reference [8]") Post-exposure prophylaxis: the board-style decisions ---------------------------------------------------- PEP is dictated less by the exposure story than by host biology. MMR within 72 hours is the preferred option for susceptible, immunocompetent people without contraindications; immune globulin within 6 days is reserved for those at highest risk or those who cannot receive live vaccine. Do not give MMR and immune globulin simultaneously. [\[9\]](#cite-9 "Reference [9]") Exposed contactBest immediate actionNuance**4-month-old infant****IMIG 0.5 mL/kg IM within 6 days** (max 15 mL). [\[10\]](#cite-10 "Reference [10]")MMR is not used for PEP in infants **younger than 6 months**. After IMIG, give the first age-eligible MMR **no earlier than 6 months later**, and only once the child is old enough for routine vaccination. [\[6\]](#cite-6 "Reference [6]")**5-year-old on maintenance chemotherapy for leukemia****IVIG 400 mg/kg within 6 days**. [\[10\]](#cite-10 "Reference [10]")Treat as **severely immunocompromised**; MMR is contraindicated, and IG is recommended **regardless of prior vaccination status**. [\[10\]](#cite-10 "Reference [10]")**12-week pregnant contact without documented immunity****IVIG 400 mg/kg within 6 days**. [\[10\]](#cite-10 "Reference [10]")Do **not** give MMR during pregnancy; arrange postpartum vaccination if still nonimmune. [\[11\]](#cite-11 "Reference [11]")**Immunocompetent susceptible child aged 6 months or older****MMR within 72 hours** is preferred. If that window is missed but exposure is high risk and still within 6 days, **IMIG** may be used with public health input. [\[9\]](#cite-9 "Reference [9]")If IG is used, the child still needs routine MMR later; **MMR and IG should not be given together**. [\[9\]](#cite-9 "Reference [9]") Beyond 6 days, you are generally no longer preventing this exposure. Management shifts to symptom surveillance and exclusion from school, daycare, or healthcare settings according to public health guidance. In healthcare settings, exposed patients without presumptive immunity may require airborne precautions from day 5 through day 21 after last exposure; if IG is used, monitoring may extend to day 28. [\[5\]](#cite-5 "Reference [5]") Clinical Application -------------------- If the index child returns a few weeks later with confusion, headache, and ataxia, the board-style answer is **acute postinfectious measles encephalitis**, often framed clinically as an ADEM-like syndrome, not SSPE. WHO surveillance standards note that encephalitic complications usually occur 2–3 weeks after rash onset. By contrast, **SSPE** is the remote, fatal neurologic sequel that generally presents **7–10 years** after the original infection. [\[12\]](#cite-12 "Reference [12]") Key Points for Board Exams -------------------------- - **Measles is infectious from 4 days before to 4 days after rash onset**; immunocompromised patients may shed longer. [\[6\]](#cite-6 "Reference [6]") - **Suspected measles in the ED is an airborne isolation emergency**, not a wait-for-confirmation diagnosis. [\[4\]](#cite-4 "Reference [4]") - **Healthcare exposure includes the same room and shared airspace for up to 2 hours after the patient leaves.** [\[5\]](#cite-5 "Reference [5]") - **Send PCR from NP/OP swab plus serum IgM**, and remember that very early IgM can be falsely negative. [\[7\]](#cite-7 "Reference [7]") - **MMR within 72 hours** is preferred for susceptible immunocompetent contacts; **IMIG within 6 days** for infants and selected others; **IVIG 400 mg/kg** for pregnancy and severe immunocompromise. [\[9\]](#cite-9 "Reference [9]") - After **IMIG**, defer MMR for **6 months**; after **IVIG**, defer for **8 months**. [\[6\]](#cite-6 "Reference [6]") Conclusion ---------- The real teaching point in pediatric measles is that the diagnosis is only half the case. The other half is systems medicine: airborne isolation, rapid exposure mapping, and correctly matched post-exposure prophylaxis for the infant, the immunocompromised child, the pregnant contact, and the susceptible but otherwise healthy child. [\[4\]](#cite-4 "Reference [4]") References (21) ------------------- 1. 1. [ www.cdc.gov/measles/data-research/index.html ](https://www.cdc.gov/measles/data-research/index.html) [↩](#cite-ref-1-1 "Back to text") 2. 2. [ www.cdc.gov/measles/hcp/communication-resources/clinical-diagnosis-fact-sheet.html ](https://www.cdc.gov/measles/hcp/communication-resources/clinical-diagnosis-fact-sheet.html) [↩](#cite-ref-2-1 "Back to text") 3. 3. [ www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-13-measles.html ](https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-13-measles.html) [↩](#cite-ref-3-1 "Back to text") 4. 4. [ www.cdc.gov/measles/hcp/clinical-overview/stay-alert-for-measles-cases.html ](https://www.cdc.gov/measles/hcp/clinical-overview/stay-alert-for-measles-cases.html) [↩](#cite-ref-4-1 "Back to text") 5. 5. [ www.cdc.gov/infection-control/hcp/measles/index.html ](https://www.cdc.gov/infection-control/hcp/measles/index.html) [↩](#cite-ref-5-1 "Back to text") 6. 6. [ www.cdc.gov/surv-manual/php/table-of-contents/chapter-7-measles.html ](https://www.cdc.gov/surv-manual/php/table-of-contents/chapter-7-measles.html) [↩](#cite-ref-6-1 "Back to text") 7. 7. [ www.cdc.gov/measles/php/laboratories/index.html ](https://www.cdc.gov/measles/php/laboratories/index.html) [↩](#cite-ref-7-1 "Back to text") 8. 8. [ www.cdc.gov/measles/hcp/clinical-overview/index.html ](https://www.cdc.gov/measles/hcp/clinical-overview/index.html) [↩](#cite-ref-8-1 "Back to text") 9. 9. [ www.cdc.gov/measles/hcp/vaccine-considerations/index.html ](https://www.cdc.gov/measles/hcp/vaccine-considerations/index.html) [↩](#cite-ref-9-1 "Back to text") 10. 10. [ www.cdc.gov/mmwr/preview/mmwrhtml/rr6204a1.htm ](https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6204a1.htm) [↩](#cite-ref-10-1 "Back to text") 11. 11. [ www.cdc.gov/vaccines-pregnancy/hcp/vaccination-guidelines/index.html ](https://www.cdc.gov/vaccines-pregnancy/hcp/vaccination-guidelines/index.html) [↩](#cite-ref-11-1 "Back to text") 12. 12. [ www.who.int/publications/m/item/vaccine-preventable-diseases-surveillance-standards-measles ](https://www.who.int/publications/m/item/vaccine-preventable-diseases-surveillance-standards-measles) [↩](#cite-ref-12-1 "Back to text") 13. 13. CDC. Measles Cases and Outbreaks. Updated March 6, 2026. 14. 14. CDC. Clinical Overview of Measles. Updated 2026. 15. 15. CDC. Interim Infection Prevention and Control Recommendations for Measles in Healthcare Settings. 2025 update. 16. 16. CDC. Laboratory Testing for Measles. June 12, 2024. 17. 17. CDC. Measles Vaccine Recommendations / Vaccine Considerations. Updated 2026. 18. 18. CDC. Manual for the Surveillance of Vaccine-Preventable Diseases, Chapter 7: Measles. 2025. 19. 19. CDC. Timing and Spacing of Immunobiologics. July 24, 2024. 20. 20. ACOG. Measles, Mumps, Rubella Vaccination and Management of Obstetric-Gynecologic Patients During a Measles Outbreak. Practice Advisory, 2024. 21. 21. WHO. Vaccine-Preventable Diseases Surveillance Standards: Measles. 2018. Next step Practice Pediatrics the way boards test ----------------------------------------- - Age‑specific differentials and management - Growth, development, and immunizations - Target weak areas with smart review [ Start practicing ](https://mdster.com/user/dashboard) [ Explore Pediatrics ](https://mdster.com/speciality/pediatrics) [ View pricing ](https://mdster.com/pricing) [ Explore features ](https://mdster.com/features) No credit card required. Full access to all features. No commitment. Cancel anytime. [ Back to all posts ](https://mdster.com/blog) Discussion () ----------------- Join the discussion [ Log in ](https://mdster.com/auth/login) or [ Sign up ](https://mdster.com/auth/register) No comments yet Be the first to share your thoughts! ![]() Related Posts ------------- [ ![Neonatal Septic Shock in the ED: A High-Yield Case Discussion](https://mdster.com/storage/blog/images/neonatal-septic-shock-in-the-ed-a-high-yield-case-discussion.jpg) Case Discussion ### Neonatal Septic Shock in the ED: A High-Yield Case Discussion An ill 18-day-old with fever, lethargy, shock, and hypoglycemia demands parallel resuscitation and sepsis management. This case reviews ED priorities, LP timing, antibiotics, HSV coverage, and board pearls. 6 min read 0 comments ](https://mdster.com/blog/neonatal-septic-shock-in-the-ed-a-high-yield-case-discussion) [ ![IBS Subtypes and Diagnosis: Rome IV, IBS-C/D, and Colonoscopy](https://mdster.com/storage/blog/images/ibs-subtypes-and-diagnosis-rome-iv-ibs-cd-and-colonoscopy.jpg) Medical Education ### IBS Subtypes and Diagnosis: Rome IV, IBS-C/D, and Colonoscopy A focused Internal Medicine review of IBS diagnosis: how to use Rome IV concepts, separate IBS-C from IBS-D and mixed IBS, and decide when colonoscopy is truly indicated. 7 min read 0 comments ](https://mdster.com/blog/ibs-subtypes-and-diagnosis-rome-iv-ibs-cd-and-colonoscopy) [ ![Congenital Hypothyroidism: Screening, Levothyroxine, Outcomes](https://mdster.com/storage/blog/images/congenital-hypothyroidism-screening-levothyroxine-outcomes.jpg) Medical Education ### Congenital Hypothyroidism: Screening, Levothyroxine, Outcomes High-yield review of congenital hypothyroidism for Pediatrics trainees, covering newborn screening pitfalls, urgent levothyroxine treatment, and developmental follow-up. 6 min read 0 comments ](https://mdster.com/blog/congenital-hypothyroidism-screening-levothyroxine-outcomes) [ ](/) Master your medical exams with evidence-based learning. [ GET IT ON Google Play ](https://play.google.com/store/apps/details?id=com.mdster.app) ### Platform - [Home](https://mdster.com) - [Features](https://mdster.com/features) - [Pricing](https://mdster.com/pricing) - [About](https://mdster.com/about) ### Resources - [Blog](https://mdster.com/blog) - [Dashboard](https://mdster.com/user/dashboard) ### Support - [Contact](https://mdster.com/contact) - [Legal & Policies](https://mdster.com/legal) - [Medical Reviewers](https://mdster.com/medical-reviewers) © 2026 MDster [ ](https://play.google.com/store/apps/details?id=com.mdster.app) [Terms](https://mdster.com/terms) [Privacy](https://mdster.com/privacy) [Editorial](https://mdster.com/editorial-policy) reCAPTCHA Protected by reCAPTCHA. Google [Privacy Policy](https://policies.google.com/privacy) and [Terms of Service](https://policies.google.com/terms) apply. Cookie Consent -------------- We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. [ Terms of Use ](https://mdster.com/terms) & [ Privacy Policy ](https://mdster.com/privacy) Accept